 |
| Osteogenesis Imperfecta Treatment Market |
Osteogenesis Imperfecta is a genetic disorder characterized by brittle bones and low bone mass that causes bones to break easily. The current treatment options available for Osteogenesis Imperfecta includes bisphosphonates and anti-resorptive drugs to increase bone density and strength and reduce fracture risk. However, there is an increase in demand for more effective treatment options with fewer side effects. Gene therapy is a promising treatment approach that targets the underlying cause of the condition at the genetic level.
The global
Osteogenesis Imperfecta Treatment Market is estimated to be valued at US$ 832.67 Mn in 2023 and is expected
to exhibit a CAGR of 4.2% over the
forecast period 2024 to 2031, as highlighted in a new report published by
Coherent Market Insights.
Market key trends:
Gene therapy is gaining traction in the treatment of Osteogenesis Imperfecta as
it helps address the root cause of the condition by delivering functional
copies of the defective collagen genes. Various gene therapy candidates are
under clinical trials aiming to deliver COL1A1 and COL1A2 genes using
adeno-associated viral vectors. Positive results from ongoing trials evaluating
the safety and efficacy of these gene therapies will further increase their
adoption over the forecast period. This is expected to fuel market growth at a
steady pace.
Segment Analysis
The global Osteogenesis Imperfecta Treatment market is dominated by the
bisphosphonates sub segment. Bisphosphonates are drugs that slow down bone
loss. They work by reducing the activity of cells that break down bone
(osteoclasts). This allows the bone-forming cells (osteoblasts) to work more
efficiently at rebuilding bone. Common bisphosphonates prescribed for
Osteogenesis Imperfecta (OI) include alendronate and pamidronate. They are the
first line of treatment for children and adults with OI to increase bone mass
and reduce fractures.
Key Takeaways
The global Osteogenesis
Imperfecta Treatment Market Share is expected to witness high growth.
The global Osteogenesis Imperfecta Treatment Market is estimated to be valued
at US$ 832.67 Mn in 2023 and is expected to exhibit a CAGR of 4.2% over the
forecast period 2024 to 2031.
Regional analysis related content comprises -
North America is currently the dominant region in the global Osteogenesis
Imperfecta Treatment market due to the growing OI patient pool and strong
presence of key players. Additionally, favorable reimbursement policies and
strong healthcare infrastructure are supporting the market growth in this
region.
Key players related content comprises -
Key players operating in the Osteogenesis Imperfecta Treatment market are
AmSurg Corp., HCA Holdings, Inc., Tenet Healthcare, Surgical Care Affiliates,
Inc., Surgery Partners, Ambulatory Surgical Centers of America, Heathway
Medical Group, Community Health Systems, Inc., and Vision Group Holdings.
For more insights, read- https://www.newsstatix.com/osteogenesis-imperfecta-treatment-market-trends-size-and-share-analysis/
For more details on the report, Read- https://cmiinfopiece.blogspot.com/2024/01/the-global-luxury-travel-market-growth.html
0 Comments